Workflow
美的集团业绩会:美国收入占比很低 库卡中国在创新和产品开发上取得突破
000333Midea Group(000333) 证券时报网·2025-04-11 13:05

Core Viewpoint - Midea Group focuses on three key areas for 2025: prioritizing overseas self-owned brands, transforming to a direct-to-consumer (DTC) model, and developing its ToB (business and industrial solutions) business [1] Group 1: Financial Performance - In 2024, Midea Group achieved total revenue of 409.1 billion yuan, a year-on-year increase of 9.5%, and a net profit attributable to the parent company of 38.5 billion yuan, up 14.3% [1] - The net cash flow from operating activities reached 60.5 billion yuan, marking a historical high [1] Group 2: Business Segmentation - Domestic business revenue was 238.1 billion yuan, a year-on-year growth of 7.68%, while overseas business revenue reached 169 billion yuan, growing by 12.01% [2] - The ToB business revenue proportion increased from 18.5% in 2020 to 25.5% in 2024, with revenue exceeding 100 billion yuan for the first time [2] Group 3: Overseas Expansion - Midea Group operates in over 200 countries and regions, with a low revenue share from the U.S. and plans to expand overseas manufacturing and new factory construction [2] - The company has established 22 R&D centers and 23 major manufacturing bases across multiple continents [2] Group 4: Robotics Industry - Midea Group ranks among the top four global industrial robot companies following its acquisition of KUKA in 2017, and has since established a robotics and automation division [2] - In 2024, KUKA China launched 27 new products, achieving significant market performance, with a domestic market share of approximately 8.2% for industrial robots [3][4] Group 5: Industry Applications - KUKA China's industrial robot business has seen rapid growth in the 3C consumer electronics sector and strengthened partnerships in the new energy vehicle industry, achieving record order volumes [4] - The company has expanded applications in logistics, including stacker robots in new industries such as tobacco and tires, and has made breakthroughs in pharmaceuticals and chemicals [4]